The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Boyko A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Alifirova V.M.
Siberian State Medical University
Lukashevich I.G.
Orden of the Red Banner of Labor City Clinical Hospital No. 1
Zaslavsky L.G.
Pavlov First Saint Petersburg State Medical University
Kotov S.V.
Vladimirsky Moscow Regional Research Clinical Institute
Malkova N.A.
State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University
Parshina E.V.
Semashko Nizhny Novgorod Regional Clinical Hospital
Prakhova L.N.
N. Bechtereva Institute of the Human Brain
Smagina I.V.
Altai State Medical University;
Regional Clinical Hospital
Totolyan N.A.
Academician I.P. Pavlov First Saint Petersburg State Medical University
Trushnikova T.N.
Wagner Perm State Medical University
Khabirov F.A.
City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education
Shchur S.G.
Municipal Filatov Clinical Hospital No. 15
Dudin V.A.
Center for Cardiology and Neurology»
Zinkina-Orikhan A.V.
AO BIOCAD
Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(7‑2): 43‑52
Views: 2623
Downloaded: 88
To cite this article:
Boyko AN, Alifirova VM, Lukashevich IG, et al. . Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry.
2023;123(7‑2):43‑52. (In Russ.)
https://doi.org/10.17116/jnevro202312307243
To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in comparison with the teriflunomide (TRF). The study of the efficacy and safety of the use of the drug DIV was carried out for 48 weeks of therapy.
The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS included 338 adult patients with RRMS distributed in a 1:1 ratio into two groups: DIV 500 mg and TRF 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks. The primary end point was «Mean annualized relapse rate 48 weeks after the last patient is randomized in the study».
321 subjects completed 48 weeks of therapy according to the study protocol. The analysis of the of efficacy data for the primary endpoint successively proved the hypothesis of superiority of the test drug DIV at a dose of 500 mg over the reference drug TRF. A rapid suppression of acute disease activity according to the brain MRI and clinical manifestations of the disease was shown after the first infusion of DIV in patients with RRMS. Thus, after 48 weeks of therapy in patients treated with DIV, there were no T1 gadolinium-enhancing lesions, while in the TRF group such lesions were observed in 20.7% (35/169) of subjects. Evaluation of the CUA per scan showed that the mean values for the estimated period were statistically significantly lower in the DIV drug group compared to the TRF group: the ratio of the adjusted per scan rates (DIV/TRF) was 0.125 [95% CI: 0.089; 0.177]. Over the 48 weeks of therapy, the proportion of subjects with relapses was 9.5% (n=16/169) in the DIV group and 19.5% (33/169) in the TRF group (p=0.0086). DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and deviations of laboratory data, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences.
The results of the clinical study indicate the high efficacy and safety of DIV in comparison with TRF.
Authors:
Boyko A.N.
Pirogov Russian National Research Medical University;
Federal Center of Brain Research and Neurotechnologies of the Federal Medical Biological Agency
Alifirova V.M.
Siberian State Medical University
Lukashevich I.G.
Orden of the Red Banner of Labor City Clinical Hospital No. 1
Zaslavsky L.G.
Pavlov First Saint Petersburg State Medical University
Kotov S.V.
Vladimirsky Moscow Regional Research Clinical Institute
Malkova N.A.
State Novosibirsk Regional Clinical Hospital;
Novosibirsk State Medical University
Parshina E.V.
Semashko Nizhny Novgorod Regional Clinical Hospital
Prakhova L.N.
N. Bechtereva Institute of the Human Brain
Smagina I.V.
Altai State Medical University;
Regional Clinical Hospital
Totolyan N.A.
Academician I.P. Pavlov First Saint Petersburg State Medical University
Trushnikova T.N.
Wagner Perm State Medical University
Khabirov F.A.
City Clinical Hospital No. 7;
Kazan State Medical Academy — Branch of the Russian Medical Academy of Continuing Professional Education
Shchur S.G.
Municipal Filatov Clinical Hospital No. 15
Dudin V.A.
Center for Cardiology and Neurology»
Zinkina-Orikhan A.V.
AO BIOCAD
Received:
30.05.2023
Accepted:
31.05.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.